A b s t r a c t
Given the molecular basis for many diseases, investigators have long used nucleic acid sequencing approaches to find the aberrations that occur in genes and, by inference, their downstream transcription and protein products. A profound revolution in medicine is underway, as advanced sequencing technology (also known as next-generation or massively parallel sequencing 1 ) has yielded ever larger amounts of data at progressively lower costs. Thus, genetic changes underlying malignancy and other diseases can be found across the majority of the genome rather than within one or a few individual genes. Within the last few years, it has become feasible (from cost and resource standpoints) to sequence all 3 billion base pairs in a human genome (whole genome sequencing [WGS] ), or the protein-coding portion (whole exome sequencing [WES] ), consisting of most of the predicted 180,000 exons, or about 1% of the overall genome. 2, 3 Other approaches include genome-wide association studies (GWAS), which have identified multiple common alleles that are associated with breast cancer risk in the general population. [4] [5] [6] Also there is transcriptome sequencing, 7 in which complementary DNA is analyzed to study the RNA transcriptome (ie, complete RNA transcribed material) associated with a genome.
Compared with earlier approaches that could analyze only one or a few genes at a time-requiring a focused hypothesis as to which genes or regions should be targetedcomprehensive genomic studies such as the aforementioned can expose a more complete spectrum of common and rare mutations underlying human malignancies on personalized and epidemiologic levels. This yields previously unknown causal or association data and helps facilitate new therapies. For example, in an attempt to find causative mutations in acute myeloid leukemia, the Washington University Medical School (WUMS) Genome Institute (St Louis, MO) used massively parallel sequencing initially to sequence the complete tumor and normal genomes from a patient with acute myeloid leukemia, with the identification of tumor-unique alterations through comparative analyses of the 2 genomes. 8 Subsequently, the Institute has performed this type of data collection and analysis on hundreds of tumor and matched normal samples. Such technology has growing relevance, given not only the continuing lack of effective therapies for many malignancies but also the increasing recognition of how genetically complex human neoplasia is. Mutations in genes associated with carcinogenesis may clearly be associated with clinical and demographic factors and impact the optimal choice of therapy. 9 Rarer or unsuspected mutations found by genome-wide approaches are important because they potentially reveal new clues to tumorigenesis and many nonneoplastic diseases (eg, inflammatory bowel disease, diabetes, cardiovascular disease, and schizophrenia) and may be a basis for novel therapies, especially for select groups of patients. Significantly, rarer mutations (which can occur as somatic mutations in disease lesions or constitutional, disease-causing mutations) could be missed without the patient and specimen numbers and consequent statistical power enabled by biorepositories and their partnerships with clinical studies. Also, rarer but significant mutations could be missed by earlier technologies not using a comprehensive genome-wide approach with the exquisite precision of DNA sequencing.
The enormous growth in genetic information created by novel approaches poses marked challenges for informatics resources and storage, but also opens up exciting new possible avenues of growth for medicine. We can envision a day in which the physical storage of tissues and biofluids will assume secondary importance to the banking of data itselfdisease and matched nondiseased specimens will undergo comprehensive genomic analysis, and the data will be stored and evaluated quickly after procurement and routinely used as a basis for personalized medical therapies. Newly generated genomic data (such as a recurrent tumor) will be rapidly compared with archived data (such as a previously resected primary tumor and reference germline) and all common and rare mutational differences identified and used in real-time decisions for therapy-the genomic analogy to the traditional pathologist role of evaluating new material under the microscope and comparing it with previous slides.
The power of genome-wide approaches carries novel ethical challenges. These challenges affect personnel who direct and manage biorepositories, along with the physicians obtaining and using the specimens, the health care facilities where the biorepository operates, and institutional review boards (IRBs) charged with reviewing the research. A unique central issue is that the research activity itself-genomic sequencing of a biosample, beyond a certain threshold and potentially including any of the aforementioned types of genetic studies-may yield enough data to identify a patient. 10 This situation stems from the enormous breadth of information that can be ascertained genome-wide, rather than from just a select number of genes using older approaches using directed polymerase chain reaction and capillary sequencing, for example. This situation is also quite distinct from pathology techniques commonly applied to banked specimens (eg, Western blotting and immunohistochemical analysis) in which the data are not sufficiently comprehensive to identify a patient. The profound implication: The traditional hierarchy of identified, coded, deidentified, and anonymized/anonymous specimens 11 on which biorepositories have based so much of their past operating practices now is largely outdated and needs to be rethought. In particular, once a banked sample is used in a genomics-based study, the notion of absolute anonymity is altered, even though, technically speaking, samples destined for this purpose can still be "deidentified" by being physically stripped of personal identifiers (and assigned a specific, highly secure coding system as a privacy safeguard) before analysis. It should be noted that although a person's genotype may be decoded by advanced molecular techniques, the person technically still cannot be identified without a second event that yields similar information and the 2 data sets then compared with each other.
Along with the patient identity concern, genomic research carries with it other risks, some previously established but now enhanced by the increasing "reach" of technology: Comprehensive genomic analysis will often reveal information about the subject that was not the intended aim of the research protocol, so-called incidental findings. 12 Also, information may be revealed that impacts third parties, ie, relatives of the participant, who might not have been part of the informed consent process. 12 Such information has a direct bearing on the future health and welfare of the subject and/or relatives. The research may also reveal unexpected information with potentially harmful consequences, such as data regarding relatedness to other family members, criminal liability, and aspects of future insurability not specifically protected by the Genetic Information Nondiscrimination Act. 13 There are mechanisms, of course, for protecting genomic data and certifying persons who have access to it, some of which are addressed further on. However, inherent in any statement or acknowledgment of risks is that no method of protection or informatics firewall can be considered absolutely secure.
Given the broad data sharing often required as part of these studies, when coupled with the identifiable nature of the data, the potential impact of these risks is further amplified. Consistent and appropriate IRB review of the proposed studies is an essential element in the success of genomic research. We solicited extensive input from genomic researchers, clinical investigators, and experts in bioethics and developed guidelines that provide investigators and IRBs with a sound framework for planning, implementing, and reviewing these important studies in a manner that facilitates the research and appropriately protects participants. Summaries of the ethical issues involved with genomic research are also available in the literature. 12, 14, 15 The implications of genomic research for biobanks are many because they must store, disburse, evaluate, and (depending on the nature of the protocol) sometimes obtain consent for samples subject to requests for genomic studies. What is it that biobanks need to know in this new era? For example, what should best practices be regarding IRB and consent issues and data sharing and submission to large restricted-access Internet-accessible databases such as the National Institutes of Health (NIH) dbGaP (Database of Genotypes and Phenotypes)? Also, what best practices and quality standards should apply to specimen processing, histopathology reviews, and nucleic acid preparations? How do these relate to the needs and expectations of customers in genomic research laboratories, and how might they evolve over time?
WUMS has been at the forefront of genomic technology, 1, 5, [16] [17] [18] especially with the presence of the Genome Institute on campus, 1 of only 3 NIH-funded large-scale sequencing centers in the United States, and Genomics and Pathology Services at Washington University St Louis (GPS@WUSTL), one of the few College of American Pathologists (CAP)-accredited/Clinical Laboratory Improvement Amendments of 1988 (CLIA)-licensed laboratories in the United States focused on the clinical application of genomic testing. The biorepository at WUMS, which works in close association with the Genome Institute on a requestdriven basis, provides a full array of laboratory services, including DNA and RNA isolation and characterization, frozen and paraffin tissue sectioning and staining, biofluid processing, pathology interpretation, and laser-capture microscopy (LCM). As such, we have gained experience with quality control, consent, and other issues relating to emerging genomics technologies and studies.
The WUMS biorepository approach is consistent with published best practice documents from the National Cancer Institute Office of Biorepositories and Biospecimen Research (OBBR) 19 and the International Society of Biological and Environmental Repositories (ISBER). 20 In these documents, sections B2.1 through 2.4 (OBBR, Biospecimen Collection, Processing, Storage, Retrieval, and Distribution), E2.0 through 3.0 (ISBER, Quality Assurance Program, Quality Standards), and J8.0 (ISBER, Specimen Collection, Processing and Retrieval) recommend biospecimen collection, storage, disbursal, and quality assessment procedures fit for the intended specimen uses. Sections C2 through C5 (OBBR, Ethical, Legal and Policy Best Practices) and K2.1 through 2.5 (ISBER, Common Principles) advise the implementation of sound informed consent activities, data access, and resource sharing policies that protect patient privacy and confidentiality.
Considerations for IRB Review and Informed Consent
The ethical principles of respect for persons, beneficence, and justice, as put forth in the Belmont Report, 21 must underpin any human subjects research effort. IRBs are charged with ensuring that all human subjects research meets the criteria for approval specified in the federal regulations at 45 CFR 46.111. Applying these criteria to the use of tissue specimens for comprehensive genetic analyses is, therefore, a central task of the IRB and one that poses challenges for informed consent, protection of participant privacy, ensuring data confidentiality, and developing plans for the disclosure (or nondisclosure) of research-related and incidental findings.
The informed consent process is the primary vehicle with which we operationalize the ethical principle of respect for persons and is required for all human subjects research unless waived by the IRB. Through this process, we ensure that potential research participants have sufficient information to decide whether or not they want to participate in the proposed research. In ❚Table 1❚, we have summarized the general IRB guidelines developed at Washington University (WU) regarding genomics and how they are handled by clinicians, investigators, and other stakeholders. ❚Table 2❚ covers specific considerations for informed consent design that are used at WU. Our guidelines ensure that all criteria for approval (45 CFR 46.111) are met and are consistent with current Office of Human Research Protections guidance. 22 Specific regulatory guidance on many genomic research issues has not yet been published but may be forthcoming.
Specimens for genomic research may be anticipated or preexisting at the time the research is proposed. While the concerns of the IRB are similar for each, different approaches may be required; therefore, our guidelines differentiate early and clearly on this point (Table 1 ). In addition, we evaluate whether the proposed plans for return of results and data and/or sample sharing are consistent with the conditions under which the sample was obtained and appropriate for the proposed research. Proposals to use archival samples are common, and the various scenarios and ways of addressing them are also summarized in Table 1 . As noted there, an occasionally encountered subset of these cases involves samples obtained for clinical purposes without consent for research or under a waiver of consent granted by the IRB. These are complex areas in which an IRB must carefully consider each study on an individual basis. Another scenario covered in Table 1 is the use of specimens from deceased persons.
Although informed consent is most often obtained by clinical investigators, an instance in which the WUMS biorepository is directly involved in the collection and consenting process is its general tumor bank protocol that samples and subsequently obtains patient consent for tissue discards specifically is to be studied, and whether data can be shared or returned. Specific "opt-in" language for genetic studies is advisable. For biobanks, the general issues are the same as for IRBs but especially relevant when the biobank is directly involved with the consent process (ie, its own general banking of discarded clinical tissues for research). Previously obtained samples with consent If participation in the genomic studies was optional, only participants agreeing to for genomic research participate can be included. The proposed studies must be consistent with the consent under which the specimen was obtained. The consent should have language consistent with any plans to share data with databases and use. If the consent is silent on this issue, the IRB should weigh the risks and benefits of the sharing plan and may require reconsent or may approve sharing without reconsent if appropriate. For samples from an external institution, the primary investigator must get assurance from the source that the proposed research is consistent with the conditions set forth in the consent under which the sample was obtained and that all necessary conditions previously described are met. Previously obtained samples without clear genomic consent Consent silent on genomic research The IRB will need to consider whether participants should be contacted and consent obtained for the proposed studies. If reconsent is needed, all elements described in the section for prospective data collection should be addressed. In unusual circumstances, the IRB may consider approving genetic research on samples for which the relevant consent is silent on the issue. In so doing, the IRB will consider whether the proposed research is sufficiently related to the original research and the extent of risks to the participant and/or relatives.
Waiver of consent
This situation is complex and handled on a case-by-case basis. Factors include whether the specimens are identifiable or anonymized, the population from which the samples were obtained, the potential risks and benefits to that population, and the conditions under which the IRB initially waived consent. If it is determined that there should be consent, all elements described in the section for prospective data collection should be addressed. In rare circumstances, the IRB may approve genetic studies on samples collected under a waiver of consent, a process that involves numerous factors. Waived consent samples may be relevant to biorepositories with general collection protocols using discards from surgical pathology because procured samples for which consent cannot be obtained (often owing to logistical challenges) fall into this category. Clinical samples for which no consent This situation involves similar considerations to the previous category, ie, should consent exists be obtained whether the risk/benefit ratio of the study justifies proceeding with a waiver of consent and what plans exist for data and sample sharing and return of research results. Samples from deceased persons Consent at time sample obtained The WU IRB considers that the conditions in the original consent document apply regardless of the subject's vital status. Therefore, these will be considered in an identical manner as described in previous sections. The IRB should consider if using the samples poses significant risks for living family members or members of the same ethnic or racial groups or in any other way could violate religious beliefs or cultural or social values or norms. Waiver of consent and clinical samples Key considerations for these scenarios: Do the conditions under which the original waiver of consent was granted address the proposed use of the specimen? Does any information suggest whether the proposed research might benefit the subjects from whom samples were obtained? Are the proposed studies likely to affect the rights of or have special significance to any specific social, ethnic, or cultural group? If so, are there appropriate measures in place to protect these groups' interests? Does the use of the sample have implications for living family members? The investigator must provide a plan that addresses data and sample sharing as described in the preceding sections. Samples from deceased persons are a common part of biobank inventories at WUMS and elsewhere.
IRB, institutional review board; WU, Washington University, St Louis, MO; WUMS, Washington University Medical School, St Louis.
from surgical pathology. 23 To clarify the issues surrounding genomic research and broaden the samples potentially available for such, the WUMS biobank, under IRB supervision, is currently modifying its consent brochure and form to include enhanced detail on the definitions and risks of genetic information ❚Figure 1❚. Also, we have added a specific supplementary question ❚Figure 2❚ covering genomic research in the signature part. Patients are free to decline this question while still agreeing to (and signing) other parts of the consent covering general nongenetic research, blood collection, and future contact. The wording in Figures 1  and 2 is similar to that already used in WUMS clinical trial protocols in which large-scale genomic analysis of procured samples is anticipated.
Return of Genetic Research Results
The personnel at biobanks must understand, in their partnerships with clinicians and protocols, whether and how research results might be returned to participants. There are unique considerations with respect to returning results from banked specimens. A full listing and discussion of these considerations is presented in ❚Table 3❚.
Along with the IRB and consent issues surrounding return of genetic research results, there are regulatory issues governing clinical laboratory testing that need attention. Although the CAP has yet to develop a formal checklist for CLIA licensing of laboratories performing clinical genomic sequencing, and although the US Food and Drug Administration does not (yet) regulate clinical genomic sequence analysis, current regulations prohibit the use of research results (that is, test results that originate in a laboratory that is not CLIA-licensed) to direct a patient's care beyond the original study consent, and, in any event, the cost of care based on research test results is virtually never covered by health insurance. A research result that has clinical relevance must therefore be verified by repeat analysis in a CLIA-licensed laboratory, which can become burdensome. (Tests with positive results that demonstrate a disease-associated mutation in one gene must be repeated, as must tests with negative results that demonstrate the lack of a mutation at other genes that could potentially impact patient treatment decisions.)
Standards for Data Sharing
Among the genetic research community, data sharing, and its promotion and facilitation across multiple groups and institutions, is of great interest because the volume of data generated in a typical study is often greater than any individual or small group can feasibly explore and because there is much scientific potential from analyzing aggregated genetic data. A key element of the NIH GWAS policy is the expectation that data from NIH-supported GWAS be deposited into its data repository, the dbGaP, at the National Center for Biotechnology Information, a component of the National Library of Medicine. The standards for submission of data to dbGaP are located online 24 : http://gwas.nih. gov/pdf/GWAS_points_to_consider_A.pdf. These standards include that the sample must have been obtained with appropriate consent specifically addressing genomic research, the deidentification of the data before its submission, and the assignment of a random, unique code to further protect privacy and confidentiality. A key requirement is that the responsible institutional official(s) of the submitting institution certify that they approve submission to the NIH GWAS data repository.
The WU IRB considers the NIH dbGaP standards to represent the current accepted norm within the research community, and all plans for genetic data sharing for WUMS studies must conform to these standards; sharing with databases is not possible for samples not obtained in accordance with these guidelines. Plans for data sharing with other investigators within and outside WU will be assessed for appropriate protections of the privacy and confidentiality of research subjects. Privately funded research may have different requirements or standards for data sharing compared with that funded by the NIH. It is important to note that whole genome and exome data are deposited into the restricted access portion of the dbGaP. Only certified investigators are allowed access, for specific objectives, and there are serious consequences for the offending party if breaches of privacy occur.
❚Table 2❚ Informed Consent Design Specifics

Requirements in consent documents
A statement that unique, individually identifiable genetic information may be generated as part of the research protocol The risks associated with genetic information, including reidentification A description of the plan, if any, with respect to return of research results A discussion of the possibility of incidental findings and the plan for disclosure (or nondisclosure) of any findings A description of the plan for data and sample sharing Considerations For studies in which the samples are yet to be collected, all of these requirements may be anticipated and must be appropriately disclosed in the informed consent. Typically the principal investigator in a clinical study will obtain consent; however, personnel at biorepositories must understand these factors so as to ensure the proper use and disbursal of samples and data. The Washington University Medical School biorepository (St Louis, MO) is currently incorporating genomics language in its general tumor banking protocol consent forms and brochure (see text and Figures 1 and 2 ).
________Yes _______No _______Patient's initials "I agree to allow my donated tissue and blood to be used for genomic research and to a llow data generated from these studies to be electronically shared with others."
❚Figure 2❚ Supplementary genetic question in the Washington University Medical School biorepository (St Louis, MO) consent form for general tumor banking from surgical pathology.
In some cases, researchers may want to use tissue or fluid from you to study your DNA and genes. This is called genomic research. Genes are a unique combination of molecules (called DNA) that we inherit from our parents. There are millions of tiny differences in our genes that determine things like our height or the color of our eyes. Some of these differences may make some people more or less likely to develop certain diseases or make people respond to medicine in different ways. Genomic research will look at the differences in specific genes or involve sequencing a large amount of your DNA. This sequencing will provide a detailed description of your DNA and is also called whole genome sequencing. This genetic information will be shared with other scientists over the internet. This is so scientists across the country can better work together to cure disease. Information will be shared two ways:
-Your genetic data will be shared through a publicly available database in a summary format grouped together with other individual's data. And, -Individual-level data will be shared through a controlled access database that requires a prior authorization process to allow access. This process is designed to ensure that only authorized people who have agreed to protect your identity will have access to the database. This is to make sure your data is used in a way consistent with what is being explained here.
Traditional information that can identify you such as your name and address will not be included in either database. However, it is possible that people could develop ways in the future to link the information in a genetic database back to you. For example, everybody's DNA (except identical twins) is unique, but some genetic information is shared with one's biological relatives, which might provide a method for comparison between databases if the information was available. Although the real risk is small, some people are concerned that this genetic information will be gathered by people other than scientists and used to discriminate or identify you. Therefore, you may choose to not have your tissue or fluid used for this type of research. We believe the risks to you and your family are low, but we are unable to specify what all of the risks might be. We believe that the benefits of learning more about cancer and other diseases outweigh these potential risks.
❚Figure 1❚ Updated language in the Washington University Medical School biorepository (St Louis, MO) consent brochure for general tumor banking, which covers the possibility of future use for genomic studies. Patients are free to accept or decline this option by affirming or declining the question shown in Figure 2 .
In the hands of the Genome Institute at WUMS, or GPS@ WUSTL, a library for WGS or WES can generally be made starting with 100 ng or more of total DNA; smaller amounts can sometimes be used to make libraries in the hands of trained specialists, but such low amounts are suboptimal. The disadvantage conferred by smaller samples is that tumors are inherently heterogeneous and multiclonal, thus raising the risk of sampling insufficiently. For example, a starting point of 1 ng typically translates to only about 5,000 to 6,000 cells. Starting with 100 ng tumor DNA would sample about 500,000 cells, a quantity that probably represents many malignancies fairly well. (We evaluate/confirm heterogeneity of the genomes of the tumor cells from the input amount regardless of whether the tumor is solid tissue or liquid/hematologic type.)
For whole genome amplification, the WUMS Genome Institute generally uses a starting point of 200 ng DNA, thereby yielding several micrograms as a result, which then is used for downstream purposes such as validating detected somatic variants in cancer genomes. Whole genome amplification itself can be done with much lower input amounts, but yields from subsequent hybrid capture procedures (for example) may be insufficient if the starting point is too scant. Minimum nucleic acid input thresholds, in general, are subject to future
Standards for Specimen Evaluation and Quality Assurance
General Issues
From a biorepository's viewpoint, it is of great interest to know the quantity (amount) and quality thresholds disbursed tissue and nucleic acid products must both meet to be useful for genomic approaches. But published standards for these considerations relating to genomic studies are currently rare to nonexistent, and evidence-based data regarding this topic remain a fertile area for investigation and reporting. Several obstacles hinder the development of such standards, including the existence of multiple analysis platforms, different ways of preparing libraries across laboratories and institutions, the diversity of tissues and tumors used as starting points, and the new, frequently evolving nature of the field. It seems a reasonable expectation that specific guidance may eventually be forthcoming from such organizations as the Food and Drug Administration and the CAP. More robust language for genomics in the standard best practice documents for biorepositories 19, 20 also would be desirable; this will perhaps also evolve from continuing knowledge and experience across institutions. Secondary users may access banked For the primary investigator (the one who Unless the finding is thought to represent a serious specimens for new research initiatives obtained the specimen) to assume and preventable threat to the welfare of the but may have no relationship with the responsibility for reporting back to the participant (the so-called duty to rescue scenario), participant, and the participant is likely participant the findings of other, secondary the most appropriate plan may be to not return not aware of the details of the study.
users would be burdensome and problematic. any findings.
Samples and/or disbursed data are These are common, up-front contraindications It generally is not possible to return findings to deidentified, or return of results may to the possibility of returning results. participants in these situations. be prohibited at some level of the protocol terms or approval.
Is there strong evidence linking the Because these factors impinge on the patient's Affirmative answers to these questions would mutation (or other finding) to a disease health and welfare and the likelihood that strengthen the case for returning results, unless phenotype, and what is its penetrance? the research result, if returned, could be other considerations override them. Is there a clinically validated, independent verified and usefully acted on, they should We strongly recommend that, unless it is an integral test that can verify the results? be considered in any plan to return, or not aim of the study, subjects be given the option Are there steps based on the information return, research findings. It should be noted to choose whether they want to learn of any that could be taken to modify risk, or that the answers to these questions and, thus, genetic findings (directly related to the study are there other important actions to be the significance of findings could shift over aims or incidental findings). This choice can be taken based on the finding? time based on scientific advances. indicated on the consent document at the time Would there be serious consequences to of enrollment. the participant of not learning and/or
If results are to be returned, the investigator acting on the information? decides which findings merit return to participants, which can be challenging and involve the considerations listed here. Borderline cases (with regard to these factors) may not have a clear consensus.
Post-data sharing plan (if return of Adequate counseling and resources are Outside expertise and a professional genetic results is planned) needed so that participants fully counselor may be important. The team should comprehend the significance of the findings. also consider whether additional confirmatory testing will be offered, whether family members can be tested, and how to cover related costs.
to a meaningful genetic output. ❚Figure 3❚ shows in schematic form how the pathologic assessment is done in the WUMS biorepository. It is important to note that macrodissection and microdissection methods, including LCM, can be used to enhance the percentage of cellularity for the tumor or other desired component, 27 as long as the user accepts the required extra time and cost. LCM techniques should consider issues of tumor geography; for example, sampling from only a small area or edge of the tumor might inadequately represent multiclonality, even if an appreciable number of cells (>5,000-50,000) is procured. From a traditional viewpoint, an ideal specimen would consist entirely of tumor cells (or cells from the disease of interest) and no necrosis. However, other histologic components are almost invariably present (such as normal tissue, dysplasia, and/or desmoplasia), and including them in the analysis is important because, among other things, it will help show if such areas truly have a nonneoplastic genomic adjustments as further refinements in genomic technology evolve, but probably the aforementioned cellular/clonal sampling issue will be rate-limiting in this regard.
Considerations for Solid and Liquid Tumors
For solid tumors, such as lung and colon carcinomas, samples for genomic techniques can be most easily obtained by sectioning directly from the tissue block (frozen or fixed), if the percentage of tumor cellularity (the percentage of overall histologically viable nuclei that belong to tumor cells) is sufficiently high. Although standards are not widespread and might evolve with further advances in the field, minimum thresholds of at least 60% tumor cellularity are common, 25 with next-generation sequencing techniques probably sufficing with a somewhat lower percentage of tumor cellularity threshold. Such histologic criteria usefully promote quality assurance consistency across sites and the value of histopathologic review. Also, they address economic and analysis limitations: Below a certain percentage of tumor cellularity threshold, WGS or WES sequencing procedures become costly (relatively speaking) because oversequencing well beyond the typical minimal coverage is needed to get sufficient reading/coverage of the tumor genome. Also, one would have to adjust bioinformatics analysis programs to unrealistic or inconvenient parameters to cope with data from specimens with a very low percentage of tumor cellularity figures.
General best practices for specimen evaluation and quality assurance from the viewpoint of the biorepository have been previously described, 26 and tissue specimens for comprehensive genetic studies are subject to rigorous quality assurance procedures at the WUMS biobank, similar to specimens for other purposes. Our most common tissue assessment is the one already described, overall percentage of tumor cellularity. This requires the involvement of a trained pathologist in the biorepository workflow, similar to how pathologists address other quality assurance functions. 23, 26 This pathologist review, currently, is of necessity a visual estimate, but image analysis software technology coupled with digital pathology could eventually provide a more precise numeric figure, especially for tumor morphologic features in which a distinct "rule set" separating tumor cells from others is feasible and can be readily implemented.
Judgments about the percentage of tumor cellularity are critical for assessing the amount of genetic "signal" coming from the tumor component and, thus, to the interpretation and reliability of the data derived from that tissue. Additional helpful evaluations include the area proportions respectively occupied by necrosis, desmoplasia, and/or admixed inflammatory cells (such as lymphocytes). As before, this helps assess the extent of genetic signal attributable to these various components. In the case of necrosis, the assessment helps determine the sample proportion that will likely not contribute ❚Figure 3❚ Schematic diagram showing how tumor cellularity and other tissue components are assessed histologically at the Washington University Medical School (St Louis, MO) for samples intended for genetic studies. The percentage area occupied by necrosis is assessed first and then excluded from the analyses of the remaining components. The necrotic area is about 10% of the total area. Of the histologically viable areas, overall tumor cellularity = 4/13 nuclei, or 31%; overall nonneoplastic cellularity = (3 + 3 + 3)/13 = 9/13, or 69% (ie, cell nuclei in the tumor, normal, and reactive/stromal areas). The necrotic area is excluded in this calculation. sample cells in this situation can be largely or exclusively clonal regardless of specific myeloblast counts. 17 An active research area currently in which the WUMS Genome Institute has been involved is the study of DNA methylation patterns and mutations in the genes responsible for such; these seem to be important in the etiology of acute myeloid leukemia and myelodysplastic syndromes. 17 
Nucleic Acid Isolation and Disbursal
On request, the WUMS biorepository may isolate, analyze, and disburse the DNA needed for genetic studies, instead of releasing the banked tissues and blood intended for such. For such requests, we use the same rigorous quality assurance procedures, backed by our strategic operating procedure documents, for the released products as we do for other intended purposes. This includes quantification of the nucleic acids and assessments of overall quality by A260/280 and A260/230 spectrophotometric absorbance ratios. The quantification is important because the biorepository should ensure that it is disbursing enough product to be fit-for-purpose.
It is important to note that in the WUMS biorepository, we have observed that quantification of DNA by A260 (NanoDrop 2000 Spectrophotometer, Thermo Scientific, Waltham, MA) can be up to 3-fold greater than the reading by fluorometric assay (Invitrogen Qubit Fluorometer, Life Technologies, Grand Island, NY), especially when the A260/A230 ratio is less than 1.7. Because many genomic investigators use fluorometric measurements as their standard, we quantify by both methods for any DNA sample intended for genomic analysis, especially if the A260/A230 ratio is less than 1.7. Also, we recommend that DNA distribution for such purposes be made at twice the minimum quantity requested if feasible, especially if quantification by fluorometric assay has not been done.
The biorepository should communicate closely with customers regarding the minimum nucleic acid quantities needed and to guard against assumptions, given varying user skills and techniques and the ever-changing nature of the field. If tissue or blood is requested as the primary deliverable with the intent that nucleic acid will be isolated by the receiving laboratory, the biobank can do helpful calculations regarding the DNA or RNA that is likely to be yielded per milligram of starting sample, [32] [33] [34] accounting for the differences in cellularity that exist across sites, for example, liver (highly cellular) compared with connective tissue (less so).
Genetic analyses of neoplastic disease frequently use matching blood specimens obtained from patients before or during therapy as a germline source of DNA for comparative purposes. This can complement or replace the use of matching nonneoplastic (adjacent) tissue for such purposes because the latter might be unavailable or histologically unsuitable. 26 Therefore, buffy coat specimens, derived from blood specimens and frozen as long-term biobank specimens, are phenotype (as one might hypothesize) or share some of the aberrations characteristic of neoplasia. Communication of the concept in Figure 3 to users is helpful, especially at the time of specimen disbursal, because it provides a visual reference for quality assurance data and the potential relevance of histologic regions and LCM procedures.
Genome-wide approaches can use fresh frozen or paraffin-embedded, formalin-fixed tissues as their starting point, whether the desired molecular substrate is DNA or RNA. Traditionally, the fresh frozen tissues have been preferred because of the better preservation and molecular integrity attributed to such tissues 28 ; however, fixed tissues have also seen successful applications in the field. 29, 30 The choice of the disposition of the starting tissue is on a case-by-case basis, involving specimen availability, the specific procedure and platform to be used, and the preferences and experience level of the investigator.
As with other investigative categories, genomic studies may use various comparative studies that access tissue bank inventories: primary vs metastatic tumors, better vs more poorly differentiated areas, and tumor vs surrounding (adjacent) normal samples. Such studies can help find the genetic changes underlying disease progression. But studies on retrospectively obtained material may be limited by the inventories typically available in tissue banks, for example, the common paucity of well-annotated primary tumors matched with metastases and other entities limited by the infrequency of surgical therapy or by competing needs from surgical pathology. 23 Prospective tissue procurements for rare or poorly represented samples, energized and emboldened by the power of genomics technology and the inevitable reach of its clinical applications, will help address this availability problem. Biorepositories will need to promote such efforts among their clinician colleagues, emphasizing their strategic importance.
The availability of histologic review and selective dissection methods for cells and tissues, combined with advancing genomic technology, opens up exciting new avenues for possible future research. 1, 31 For example, the genomes of single cells could be analyzed and compared, yielding new insights into geographic or regional differences within solid tumors, as well as multiclonality generally. Also, gene expression profiles and patterns could be examined across a wide swath of developmental and adult tissues and histologic compartments.
Liquid neoplasias such as leukemias and myelodysplastic syndromes pose many of the same challenges for genomic studies as do other disease types. The WUMS biorepository maintains active collection and storage protocols for bone marrow and peripheral blood samples that enable studies of these disease entities. One emerging issue relevant to morphologic parameters is that myeloblast counts are often not a good indicator of clonality or mutational prevalence, particularly for myelodysplastic syndrome; in particular, the majority of frequently disbursed by the WUMS biobank for genomic studies. Evidence from the literature indicates that such buffy coat specimens are a stable source for DNA with yields suitable for many categories of genomic tests, especially when stored for up to 9 years at -80°C. 35 Recent technical advances will have important consequences for biorepositories. The development of inexpensive instruments (eg, the MiSeq, Illumina, San Diego, CA; and the Ion Torrent, Life Technologies, San Francisco, CA) that can perform high-throughput sequence analysis faster and cheaper than current platforms will make comprehensive genomic analysis accessible to a much larger group of laboratories and will stimulate application of genomic sequence analysis to a much broader range of diseases. Similarly, recognition that sequence analysis of panels of genes, instead of whole exomes or whole genomes, is sufficient to address many research questions 36, 37 will greatly simplify data analysis and thereby increase the number of laboratories that perform genomic studies and, thus, increase demand for appropriately characterized molecular specimens from biorepositories.
